551 related articles for article (PubMed ID: 9927575)
1. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.
Galmiche MC; Goenaga J; Wittek R; Rindisbacher L
Virology; 1999 Feb; 254(1):71-80. PubMed ID: 9927575
[TBL] [Abstract][Full Text] [Related]
2. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin.
Bell E; Shamim M; Whitbeck JC; Sfyroera G; Lambris JD; Isaacs SN
Virology; 2004 Aug; 325(2):425-31. PubMed ID: 15246280
[TBL] [Abstract][Full Text] [Related]
3. Antibody neutralization of the extracellular enveloped form of vaccinia virus.
Law M; Smith GL
Virology; 2001 Feb; 280(1):132-42. PubMed ID: 11162827
[TBL] [Abstract][Full Text] [Related]
4. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge.
Hooper JW; Custer DM; Schmaljohn CS; Schmaljohn AL
Virology; 2000 Jan; 266(2):329-39. PubMed ID: 10639319
[TBL] [Abstract][Full Text] [Related]
5. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.
Pulford DJ; Gates A; Bridge SH; Robinson JH; Ulaeto D
Vaccine; 2004 Sep; 22(25-26):3358-66. PubMed ID: 15308360
[TBL] [Abstract][Full Text] [Related]
6. Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R.
Aldaz-Carroll L; Whitbeck JC; Ponce de Leon M; Lou H; Hirao L; Isaacs SN; Moss B; Eisenberg RJ; Cohen GH
J Virol; 2005 May; 79(10):6260-71. PubMed ID: 15858010
[TBL] [Abstract][Full Text] [Related]
7. Extracellular enveloped vaccinia virus escapes neutralization.
Ichihashi Y
Virology; 1996 Mar; 217(2):478-85. PubMed ID: 8610439
[TBL] [Abstract][Full Text] [Related]
8. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates.
Hooper JW; Custer DM; Thompson E
Virology; 2003 Feb; 306(1):181-95. PubMed ID: 12620810
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of B5R mutants of rabbitpox virus in vivo is related to impaired growth and not an enhanced host inflammatory response.
Stern RJ; Thompson JP; Moyer RW
Virology; 1997 Jun; 233(1):118-29. PubMed ID: 9201221
[TBL] [Abstract][Full Text] [Related]
10. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.
Clark KM; Johnson JB; Kock ND; Mizel SB; Parks GD
Virology; 2011 Oct; 419(2):97-106. PubMed ID: 21885079
[TBL] [Abstract][Full Text] [Related]
11. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
[TBL] [Abstract][Full Text] [Related]
12. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.
Golden JW; Josleyn MD; Hooper JW
Vaccine; 2008 Jun; 26(27-28):3507-15. PubMed ID: 18485547
[TBL] [Abstract][Full Text] [Related]
13. Vaccinia virus gene A36R encodes a M(r) 43-50 K protein on the surface of extracellular enveloped virus.
Parkinson JE; Smith GL
Virology; 1994 Oct; 204(1):376-90. PubMed ID: 8091668
[TBL] [Abstract][Full Text] [Related]
14. The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence.
Engelstad M; Smith GL
Virology; 1993 Jun; 194(2):627-37. PubMed ID: 8503178
[TBL] [Abstract][Full Text] [Related]
15. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
He Y; Manischewitz J; Meseda CA; Merchlinsky M; Vassell RA; Sirota L; Berkower I; Golding H; Weiss CD
J Infect Dis; 2007 Oct; 196(7):1026-32. PubMed ID: 17763325
[TBL] [Abstract][Full Text] [Related]
16. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host.
Fang M; Cheng H; Dai Z; Bu Z; Sigal LJ
Virology; 2006 Feb; 345(1):231-43. PubMed ID: 16256161
[TBL] [Abstract][Full Text] [Related]
17. In vitro human CD4+ T cell response to the vaccinia protective antigens B5R and A33R.
Sirven P; Castelli FA; Probst A; Szely N; Maillere B
Mol Immunol; 2009 Apr; 46(7):1481-7. PubMed ID: 19193441
[TBL] [Abstract][Full Text] [Related]
18. Pathogenicity and immunogenicity in mice of vaccinia viruses mutated in the viral envelope proteins A33R and B5R.
Gurt I; Abdalrhman I; Katz E
Antiviral Res; 2006 Mar; 69(3):158-64. PubMed ID: 16406098
[TBL] [Abstract][Full Text] [Related]
19. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
Kaufman DR; Goudsmit J; Holterman L; Ewald BA; Denholtz M; Devoy C; Giri A; Grandpre LE; Heraud JM; Franchini G; Seaman MS; Havenga MJ; Barouch DH
J Virol; 2008 Jul; 82(14):6829-37. PubMed ID: 18448519
[TBL] [Abstract][Full Text] [Related]
20. Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF.
Raviprakash K; Marques E; Ewing D; Lu Y; Phillips I; Porter KR; Kochel TJ; August TJ; Hayes CG; Murphy GS
Virology; 2001 Nov; 290(1):74-82. PubMed ID: 11883007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
